International Isotopes gets go-ahead

Article

Radioisotope manufacturer International Isotopes of Denton, TX, reported last month that the Texas Department of Public Health's Bureau of Radiation Control has approved a license amendment for the production of small quantities of thallium-201, a

Radioisotope manufacturer International Isotopes of Denton, TX, reported last month that the Texas Department of Public Health's Bureau of Radiation Control has approved a license amendment for the production of small quantities of thallium-201, a radioisotope used for the diagnosis of heart disease and cardiac function. The isotope will be manufactured using International Isotopes' linear accelerator, as well as its cyclotron.

The approval allows the firm to begin preliminary shipments of thallium and other radiochemicals to pharmaceutical companies, a crucial step in establishing itself as a reliable provider of raw pharmaceutical material, according to Carl Seidel, president and CEO. International Isotopes will begin shipping thallium in early March, but declined to name particular customers.

Recent Videos
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Related Content
© 2025 MJH Life Sciences

All rights reserved.